Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 85,262 |
|
|||||
| News | - | ||||||
| Day High | 1.4277 | Low High |
|||||
| Day Low | 1.31 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| eFFECTOR Therapeutics Inc | EFTR | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.07 | -5.07% | 1.31 | 23:00:08 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.392 | 1.31 | 1.4277 | 1.31 | 1.38 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 476 | 85,262 | US$ 1.38 | US$ 117,584 | - | 1.31 - 36.25 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 17:09:08 | 10 | US$ 1.37 | USD |
eFFECTOR Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 3.92M | 3.00M | - | 0 | -35.81M | -11.95 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
eFFECTOR Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/21/2024 | 16:20 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/21/2024 | 16:00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/09/2024 | 19:14 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 1/30/2024 | 07:31 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/26/2024 | 15:40 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/26/2024 | 15:32 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 1/10/2024 | 07:06 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 1/10/2024 | 07:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/08/2024 | 07:19 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 1/08/2024 | 07:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/08/2023 | 07:31 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 12/08/2023 | 07:23 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EFTR Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.72 | 1.73 | 1.31 | 1.52 | 146,707 | -0.41 | -23.84% |
| 1 Month | 2.09 | 2.13 | 1.31 | 1.74 | 96,380 | -0.78 | -37.32% |
| 3 Months | 11.00 | 16.882 | 1.31 | 3.91 | 374,480 | -9.69 | -88.09% |
| 6 Months | 14.62 | 17.75 | 1.31 | 9.84 | 833,621 | -13.31 | -91.04% |
| 1 Year | 31.00 | 36.25 | 1.31 | 15.05 | 954,700 | -29.69 | -95.77% |
| 3 Years | 475.00 | 1,010.50 | 1.31 | 116.34 | 763,994 | -473.69 | -99.72% |
| 5 Years | 475.00 | 1,010.50 | 1.31 | 116.34 | 763,994 | -473.69 | -99.72% |
eFFECTOR Therapeutics Description
| eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California. |
